China-based Contract Development and Manufacturing Organization (CDMO) Chime Biologics Ltd has announced a strategic cooperation with South Korean biotech firm Panolos Bioscience. The partnership aims to accelerate the development of multi-specific proteins, although no financial details have been disclosed.
Focus on Multi-Specific Therapeutics
Panolos Bioscience is a biopharmaceutical company specializing in the development of multi-specific therapeutics for the treatment of cancer, autoimmune diseases, and rare diseases. This collaboration with Chime marks a significant step in advancing the pipeline of novel multi-specific protein drugs.
PB203: A Novel Multi-Specific Protein Drug for Solid Tumors
Panolos has entered into a collaboration with Chime for the development of PB203, a multi-specific protein drug targeting solid tumors such as pancreatic ductal adenocarcinoma (PDAC) and intrahepatic cholangiocarcinoma (ICC). Currently in the preclinical stage, PB203 plans to conduct Phase I clinical trials in the US.
Chime’s Comprehensive Biologic CMC Solution
Chime will provide a one-stop biologic Chemical, Manufacturing, and Control (CMC) solution for the development and manufacturing of PB203. This includes cell line development, process development, and GMP manufacturing services. The process will leverage Chime’s unique CHOrus platform, which is known for its highly productive, rapid, and stable cell line development capabilities. This platform allows for the selection of optimal stable expression clones based on expression titer and quality, ensuring the development of high-quality biologics.-Fineline Info & Tech
